Emerging Therapeutic Innovations for Vitiligo Treatment
Vitiligo is a chronic autoimmune disorder with a multifactorial etiology, typically manifesting as localized or generalized hypopigmentation or depigmentation of the skin and mucous membranes. The pathogenesis of vitiligo is complex and significantly impacts patients’ quality of life. Although tradi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/47/3/191 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850089664573079552 |
|---|---|
| author | Weiran Li Penghao Dong Guiyuan Zhang Junjie Hu Sen Yang |
| author_facet | Weiran Li Penghao Dong Guiyuan Zhang Junjie Hu Sen Yang |
| author_sort | Weiran Li |
| collection | DOAJ |
| description | Vitiligo is a chronic autoimmune disorder with a multifactorial etiology, typically manifesting as localized or generalized hypopigmentation or depigmentation of the skin and mucous membranes. The pathogenesis of vitiligo is complex and significantly impacts patients’ quality of life. Although traditional treatments such as hormone therapy, topical medications, and laser therapy can help control the disease to some extent, their outcomes remain unsatisfactory. Therefore, ongoing research is crucial to explore and develop novel treatment strategies while assessing their efficacy and safety. This review aims to classify and summarize various new candidate drugs for vitiligo currently undergoing clinical trials, providing a reference for clinical practice. Recent advancements in the understanding of the pathogenesis of vitiligo have facilitated the development of potential treatment strategies, such as Janus kinase inhibitors, cytokine blockers, and agents targeting tissue-resident memory or regulatory T cells. These emerging therapies offer hope to patients with vitiligo, though further investigation is needed to confirm their safety, efficacy, and optimal treatment regimens. |
| format | Article |
| id | doaj-art-e302d00e530246f49c320a3801137cdf |
| institution | DOAJ |
| issn | 1467-3037 1467-3045 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj-art-e302d00e530246f49c320a3801137cdf2025-08-20T02:42:42ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-03-0147319110.3390/cimb47030191Emerging Therapeutic Innovations for Vitiligo TreatmentWeiran Li0Penghao Dong1Guiyuan Zhang2Junjie Hu3Sen Yang4Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, ChinaInstitute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, ChinaInstitute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, ChinaInstitute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, ChinaInstitute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, ChinaVitiligo is a chronic autoimmune disorder with a multifactorial etiology, typically manifesting as localized or generalized hypopigmentation or depigmentation of the skin and mucous membranes. The pathogenesis of vitiligo is complex and significantly impacts patients’ quality of life. Although traditional treatments such as hormone therapy, topical medications, and laser therapy can help control the disease to some extent, their outcomes remain unsatisfactory. Therefore, ongoing research is crucial to explore and develop novel treatment strategies while assessing their efficacy and safety. This review aims to classify and summarize various new candidate drugs for vitiligo currently undergoing clinical trials, providing a reference for clinical practice. Recent advancements in the understanding of the pathogenesis of vitiligo have facilitated the development of potential treatment strategies, such as Janus kinase inhibitors, cytokine blockers, and agents targeting tissue-resident memory or regulatory T cells. These emerging therapies offer hope to patients with vitiligo, though further investigation is needed to confirm their safety, efficacy, and optimal treatment regimens.https://www.mdpi.com/1467-3045/47/3/191vitiligopathogenesisemerging drugsJAK inhibitorsimmunotherapy |
| spellingShingle | Weiran Li Penghao Dong Guiyuan Zhang Junjie Hu Sen Yang Emerging Therapeutic Innovations for Vitiligo Treatment Current Issues in Molecular Biology vitiligo pathogenesis emerging drugs JAK inhibitors immunotherapy |
| title | Emerging Therapeutic Innovations for Vitiligo Treatment |
| title_full | Emerging Therapeutic Innovations for Vitiligo Treatment |
| title_fullStr | Emerging Therapeutic Innovations for Vitiligo Treatment |
| title_full_unstemmed | Emerging Therapeutic Innovations for Vitiligo Treatment |
| title_short | Emerging Therapeutic Innovations for Vitiligo Treatment |
| title_sort | emerging therapeutic innovations for vitiligo treatment |
| topic | vitiligo pathogenesis emerging drugs JAK inhibitors immunotherapy |
| url | https://www.mdpi.com/1467-3045/47/3/191 |
| work_keys_str_mv | AT weiranli emergingtherapeuticinnovationsforvitiligotreatment AT penghaodong emergingtherapeuticinnovationsforvitiligotreatment AT guiyuanzhang emergingtherapeuticinnovationsforvitiligotreatment AT junjiehu emergingtherapeuticinnovationsforvitiligotreatment AT senyang emergingtherapeuticinnovationsforvitiligotreatment |